Ravi Vij

503 total citations
13 papers, 171 citations indexed

About

Ravi Vij is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ravi Vij has authored 13 papers receiving a total of 171 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Ravi Vij's work include Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ravi Vij is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (5 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ravi Vij collaborates with scholars based in United States, Germany and United Kingdom. Ravi Vij's co-authors include Alvin Wong, Rubén Niesvizky, Ashraf Badros, Thomas Martin, Jeffrey A. Zonder, Lori Kunkel, Jesse Keller, John F. DiPersio, H. Jean Khoury and R Brown and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Ravi Vij

10 papers receiving 170 citations

Peers

Countries citing papers authored by Ravi Vij

Since Specialization

Citations

This map shows the geographic impact of Ravi Vij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi Vij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi Vij more than expected).

Fields of papers citing papers by Ravi Vij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi Vij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi Vij. The network helps show where Ravi Vij may publish in the future.

Co-authorship network of co-authors of Ravi Vij

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi Vij. A scholar is included among the top collaborators of Ravi Vij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi Vij. Ravi Vij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Michael Slade, (unknown), Abir Khaled, Mark A. Fiala, (unknown), Mark A. Zaydman, Fei Wan, Mark A. Schroeder, Keith Stockerl‐Goldstein, Liqiang Yang, Ravi Vij	0
2	Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). 2025 ·Journal of Clinical Oncology ·Muhamed Baljević, Peter M. Voorhees, (unknown), Anita D’Souza, Alfred Chung, Eben I. Lichtman, Hana Safah, Katja Weisel, Ravi Vij, Hira Mian, Hila Magen, Emma Searle, (unknown), Neha Korde, Saurabh Chhabra, (unknown), (unknown), (unknown), (unknown), Shaji Kumar	2
3	Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). 2024 ·Journal of Clinical Oncology ·(unknown), Peter M. Voorhees, Anita D’Souza, Alfred Chung, Sascha A. Tuchman, Hana Safah, (unknown), Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, (unknown), (unknown), (unknown), (unknown), Aarif Ahsan, Xin Li, Ziyi Jin, Chetasi Talati, Shaji Kumar	8
4	Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma 2024 ·Blood ·(unknown), (unknown), Keith Stockerl-Goldstein, Mark A. Schroeder, (unknown), Ravi Vij, Michael Slade	0
5	P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 2023 ·HemaSphere ·Katja Weisel, Anita D’Souza, David D. Hurd, Peter M. Voorhees, Raphael Teipel, Alfred Chung, Cesar Rodriguez, (unknown), Neha Korde, Hana Safah, Orlando F. Bueno, (unknown), (unknown), (unknown), Jeremy A. Ross, Shane Lee, Ziyi Jin, (unknown), Shaji Kumar, Ravi Vij	1
6	P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT 2022 ·HemaSphere ·(unknown), H. Goldschmidt, D. Cella, Martina Petrucci, Philippe Moreau, (unknown), A. Juarez-Garcia, (unknown), Junchen Gu, (unknown), Sujith Dhanasiri, (unknown), (unknown), (unknown), Karthik Ramasamy, Ravi Vij	0
7	PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA 2022 ·HemaSphere ·Ravi Vij, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
8	Targeted treatments for multiple myeloma: specific role of carfilzomib 2015 ·Pharmacogenomics and Personalized Medicine ·Ravi Vij, (unknown), Jesse Keller	18
9	Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT in newly diagnosed multiple myeloma (NDMM) 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Andrzej Jakubowiak, Kent A. Griffith, Jagoda Jasielec, Cara A. Rosenbaum, Jesús G. Berdeja, Ravi Vij, Noopur Raje, Donna Reece, Shaun Rosebeck, Sandeep Gurbuxani, Dominik Dytfeld, Todd M. Zimmerman	2
10	Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety 2013 ·Leukemia ·Ashraf Badros, Ravi Vij, Thomas Martin, Jeffrey A. Zonder, Lori Kunkel, (unknown), (unknown), Alvin Wong, Rubén Niesvizky	116
11	A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma 2009 ·Clinical Lymphoma & Myeloma ·(unknown), Renee Leduc, Marybeth Nelson, Amy Sam, Stacey Chuma, (unknown), Kelly O’Connor, (unknown), (unknown), R Schlossman, Brianna Harris, D Warren, (unknown), Jacob P. Laubach, Ravi Vij, Erica Campagnaro, Ann Birner, (unknown), KC Anderson, PG Richardson	1
12	A377 Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003) 2009 ·Clinical Lymphoma & Myeloma ·Sundar Jagannath, Ravi Vij, (unknown), George Somlo, Andrzej Jakubowiak, Tony Reiman, (unknown), (unknown), (unknown), Scott Cruickshank, Rowena Schwartz, Lori Kunkel, David Siegel	1
13	Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation 2003 ·Biology of Blood and Marrow Transplantation ·H. Jean Khoury, Kathryn Trinkaus, M-J Zhang, (unknown), R Brown, Ravi Vij, Lawrence T. Goodnough, (unknown), H. L. McLeod, Shalini Shenoy, Mary M. Horowitz, John F. DiPersio	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact